Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

In vitro evaluation of biocompatibility and degradation of human blood-derived scaffolds by seeding of mouse embryo fibroblasts

Behnia-Willison F., Aryan P., Salehnia M., Willison N., Nguyen T., Tansu N.

Laboratory Study, published in PNAS Nexus (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
PNAS Nexus (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41867896
PMCID
PMC13001638
DOI
10.1093/pnasnexus/pgag069

Abstract (original English)

This study highlights the biocompatibility and biodegradability of a novel blood-derived scaffold for regenerative medicine. The scaffold supports cell integration, reduces immune rejection risks, and offers potential as a customizable solution for tissue repair and regeneration. As an autologous scaffold, it offers significant advantages, including reduced risk of immune rejection and improved integration with host tissues. These findings lay the foundation for further investigation of this scaffold as a safe and customizable solution for tissue repair and regeneration in clinical settings. The key objective was to evaluate the interaction of a novel blood-derived scaffold with mouse embryo fibroblasts for potential clinical use. Scaffolds prepared from human donor blood were seeded with fibroblasts. Cell survival and proliferation were assessed using the MTT assay, while morphological studies were conducted via light microscopy, scanning electron microscopy, and laser confocal scanning microscopy. Biodegradation was tested in the presence and absence of enzymes. We found that fibroblasts attached and penetrated the scaffold with a density of 1 cell per 10 3 µm 2 (≈1,000 cells/mm 2 ). Concentrations of interleukin-6 and transforming growth factor β were significantly higher in the experimental group ( P < 0.05), whereas the levels of interleukin-1 and tumor necrosis factor-alp

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.